Equecabtagene autoleucel
Eque-cel is a Chinese CAR-T for multiple myeloma that has returned after at least three treatments, approved in 2023 and notable for durable responses in a large single-arm trial.
Overview
Developed by IASO Bio with Innovent from work at Tongji Hospital in Wuhan, and approved by the NMPA in June 2023 for relapsed or refractory multiple myeloma after three or more lines including a proteasome inhibitor and an immunomodulatory drug. The FUMANBA-1 trial (JAMA Oncology 2024) reported objective responses in about 96% of infused patients with deep, minimal residual disease-negative remissions and a low rate of severe cytokine release syndrome. It competes in China with ciltacabtagene autoleucel and zevorcabtagene autoleucel; it also holds FDA regenerative medicine advanced therapy designation.
Compare all products across the US, EU, UK, Japan, China and Australia →
Approvals
| Region | Year | Indication |
|---|---|---|
| China | 2023 | Relapsed or refractory multiple myeloma after three or more lines including a proteasome inhibitor and an immunomodulatory agent |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
Latest papers
topQuery for this drug: (TITLE:"Equecabtagene autoleucel" OR ABSTRACT:"Equecabtagene autoleucel" OR TITLE:"Fucaso" OR ABSTRACT:"Fucaso" OR TITLE:"eque-cel" OR ABSTRACT:"eque-cel" OR TITLE:"CT103A" OR ABSTRACT:"CT103A") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Equecabtagene autoleucel, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductFulzerasib
Shares Michael Yu (Yu De-Chao), Innovent Biologics and the tag china.
- TrialLUMMICAR STUDY 1
Shares BCMA, Multiple myeloma, CAR-T cell therapy and the tag china.
- ProductSintilimab
Shares Michael Yu (Yu De-Chao), Innovent Biologics and the tag china.
- ProductZevorcabtagene autoleucel
Shares BCMA, Multiple myeloma, CAR-T cell therapy and the tag china.
- TrialLEGEND-2
Shares BCMA, Multiple myeloma, CAR-T cell therapy and the tag china.
- PersonZonghai Li
Shares BCMA, Multiple myeloma, CAR-T cell therapy and the tag china.
- CompanyGenFleet Therapeutics
Shares Innovent Biologics and the tag china.
- TrialORIENT-11
Shares Innovent Biologics and the tag china.